EU Approves Takeda’s Dengue Vaccine

The European Commission (EC) has approved Takeda’s dengue Qdenga vaccine for individuals four years and older in preventing dengue, a mosquito-borne disease that can cause severe bleeding and shock.

The approval was supported by results from multiple clinical trials in which the vaccine prevented 80 percent of symptomatic dengue cases at 12 months after vaccination.

The Qdenga vaccine is based on a weakened form of the dengue serotype 2 virus and is designed to protect against four dengue virus serotypes.